Plain-English translation of NCT06861478 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether omeprazole or pantoprazole—medications that reduce stomach acid—should be continued or stopped during a hospital stay for patients with cirrhosis who have life-threatening bleeding from variceal bleeding. Doctors are unsure whether these medications are truly safe and helpful for this specific group of patients, so researchers are comparing what happens to patients who receive the medication versus those who don't.
There is ongoing debate among doctors about whether acid-reducing medication is safe for patients with severe liver disease who are bleeding from the stomach. This study aims to answer that question by carefully measuring complications like infections, kidney problems, and rebleeding in both treatment groups.
You likely qualify if…
You likely don't qualify if…
After you are stabilized and a doctor confirms the source of your bleeding with an endoscopy, you will be randomly assigned to either continue taking the acid-reducing medication or stop taking it during your hospital stay. All other standard treatments—such as vasoactive drugs, antibiotics, and endoscopic procedures—will remain unchanged. The research team will carefully monitor your condition, collecting blood tests, imaging, and noting any complications like infection, kidney problems, or rebleeding until you leave the hospital.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Mexico